Life Science Partnering
What are the key drivers that dictate “value” creation? What are the pitfalls to avoid on the path to acquisition, partnership or joint commercialization models? Senior industry leaders will share their perspectives at Biotech Showcase™ 2015 biotechnology investor and partnering conference January 12–14, 2015 in San Francisco. The panel discussion, entitled “Value creation: Private and Public investment strategies and stage gates for success,” will focus on defining investment strategies.
Do you have questions for the investors on how they perceive value? Post them here. And read more at http://bit.ly/11gFwrs
We've spent the past few days in Frankfurt covering BIO-Europe®. Catch up on our coverage below!
Video: A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014: http://bit.ly/1xYBC0T
Video: Biopharma strategy: More focus, more value? http://bit.ly/1yQDrhg
Post: #BEU14: Funding in Europe and deals to change business: http://bit.ly/1qpbNmz
Post: #BEU14: Top Trends from Day 1 http://bit.ly/1qpbVCy
Today at the partnering 360® blog, Merck Serono shares a few of the ways they've seen partnering change over the past few years. Head over to the blog and see what they think: http://www.partnering360.com/blog/2014/10/28/shifting-models-in-life-science-partnering/ and then share how you've seen it change.
Ahead of BIO-Europe, Eric von Hoffe, President of Antigen Express, sat down with Insight. Head to the blog to find out more about their technology: http://www.partnering360.com/blog/2014/10/24/insight-into-antigen-express-immunotherapy/
We took a brief moment to check out a few of the things that BIO-Europe® companies including Apricus Biosciences, arGEN-X and RedHill Biopharma have been up to ahead of next week's event.